Celularity Management
Management criteria checks 1/4
Celularity's CEO is Bob Hariri, appointed in Jul 2021, has a tenure of 2.75 years. total yearly compensation is $5.24M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 13.07% of the company’s shares, worth $8.74M. The average tenure of the management team and the board of directors is 1.8 years and 2.8 years respectively.
Key information
Bob Hariri
Chief executive officer
US$5.2m
Total compensation
CEO salary percentage | 22.9% |
CEO tenure | 2.8yrs |
CEO ownership | 13.1% |
Management average tenure | 1.8yrs |
Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts
Dec 14Celularity: Celgene Spin-Off Developing Allogeneic Therapies
Sep 06CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2023 | n/a | n/a | -US$181m |
Jun 30 2023 | n/a | n/a | -US$83m |
Mar 31 2023 | n/a | n/a | US$13m |
Dec 31 2022 | US$5m | US$1m | US$14m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | US$31m |
Mar 31 2022 | n/a | n/a | -US$81m |
Dec 31 2021 | US$22m | US$1m | -US$100m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$188m |
Mar 31 2021 | n/a | n/a | -US$260m |
Dec 31 2020 | US$3m | US$1m | -US$208m |
Compensation vs Market: Bob's total compensation ($USD5.24M) is above average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Hariri (64 yo)
2.8yrs
Tenure
US$5,242,529
Compensation
Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 2.8yrs | US$5.24m | 13.07% $ 8.7m | |
Chief Financial Officer | 2.8yrs | US$1.71m | 0.034% $ 22.7k | |
Senior EVP | 1.5yrs | US$2.50m | 0.0049% $ 3.3k | |
Chief Technology Officer | less than a year | no data | no data | |
SVP of Investor Relations | no data | no data | no data | |
Executive VP | 1.8yrs | no data | 0.0034% $ 2.3k | |
President of Degenerative Diseases | 2.8yrs | no data | 0.0025% $ 1.7k | |
Executive VP | 1.5yrs | no data | 0.52% $ 344.5k | |
Senior Vice President of Clinical Dev. Immunology & Drug Safety | 2.3yrs | no data | no data | |
Senior Vice President of Technical Operations | less than a year | no data | no data | |
Treasurer | no data | no data | no data | |
Secretary | no data | no data | no data |
1.8yrs
Average Tenure
53yo
Average Age
Experienced Management: CELU's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 2.8yrs | US$5.24m | 13.07% $ 8.7m | |
Independent Director | 1.8yrs | US$627.68k | 0.017% $ 11.1k | |
Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
Independent Director | 6.3yrs | US$373.00k | 0.85% $ 566.5k | |
Independent Director | 2.8yrs | US$353.50k | 0.51% $ 339.9k | |
Independent Director | 4.9yrs | US$371.00k | 0.039% $ 26.1k | |
Director | less than a year | no data | no data | |
Co-Chairman of Scientific Advisory Board | no data | no data | no data |
2.8yrs
Average Tenure
66yo
Average Age
Experienced Board: CELU's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.